## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. 6334

In re Patent Application of

|             |          | ippinoution or   | Committee                       | 11110. 0001                  |
|-------------|----------|--|---------------------------------|------------------------------|
| MEU         | TERMA    | NS et al   | Atty. Ref.:                     | 5066-7                       |
| Seria       | I No. 10 | 0/531,303  | Group:                          | 1623                         |
| Filed       | : N      | ovember 21, 2005   | Examiner:                       | Goon, S.Y.                   |
| For:        | CARE     | BOHYDRATE BASED ANTI-BACTERIA  | LS                              |                              |
|             |          | * * * * * *  | * * * *                         |                              |
| P.O.        | Box 145  | er for Patents<br>50<br>/A 22313-1450  | August 10,                      | 2009                         |
| Sir:        |          |  |                                 |                              |
|             |          | INFORMATION DISCLOSURE   | STATEMEN                        | Ī                            |
|             | 1.       | PTO/SB/08a Pursuant to 37 CFR 1.9 [within 3 months of filling or prior to 1st  |                                 | on the merits] N/C           |
|             | 2.(a)    | Statement Pursuant to 37 CFR 1.976 [before Final Office Action or Allowand Statement or Rule 17(p) fee)]   |                                 | ule 97(e)<br>N/C             |
| $\boxtimes$ | 2 .(b)   | Fee Payment Pursuant to 37 CFR 1. [before Final Office Action or Allowand Statement or Rule 17(p) fee)]  |                                 | ule 97(e)<br><i>\$180.00</i> |
|             | 3.       | Pursuant to 37 CFR 1.97(d)<br>[after Final Office Action or Allowance<br>Statement and Rule 17(p) fee), but be   |                                 |                              |
| 37 C.       |          | llowing are submitted in the above-iden<br>1.97 and 1.98:  | tified applicati                | on in compliance with        |
| $\boxtimes$ | 1        | A list of documents on Form PTO/SB/08<br>may be required) of each identified docu<br>concise explanation of each non-English<br>as a Search Report) is enclosed herewi | iment and a ti<br>n language do | anslation or a               |

The U.S. patent document listed on the attached PTO/SB/08a Form shares multiple inventors with the present application (Application No. 10/531,303) and is understood by the undersigned to be owned by Alchemia Limited, as is Application No. 10/531,303. The non-U.S. patent documents listed on the attached Form are of record in the listed U.S. patent document (U.S. Published Appln. No. 2006/0121530).

| his p       | paper   | is sut   | omitted in accordance with:   |  |  |
|-------------|---|--|---|--|--|
|             | 5.  | 37 CFR 1.97(b): [within 3 months of filling or prior to 1st Office Action] |   |  |  |
| $\boxtimes$ | 6.  | 37 (<br>and  | CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];   |  |  |
|             |   | a)   | The required Statement made in item 8 below; or   |  |  |
|             | $\boxtimes$   | b)   | The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.  |  |  |
|             | 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule Statement <u>and</u> Rule 17(p) fee), but before final fee payment]; and |  | CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) tement <u>and</u> Rule 17(p) fee), but before final fee payment]; and  |  |  |
|             |   | a)   | The fee (\$180.00) required by 37 CFR $\S1.17(p)$ is submitted herewith; and  |  |  |
|             |   | b)   | The required Statement is stated in item 8 below.   |  |  |
|             | 8.  | Statement under 37 CFR 1.97(e)   |   |  |  |
|             |   | a)   | The undersigned attorney of record hereby certifies uncer 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or |  |  |
|             |   | b)   | No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this IDS.   |  |  |

MEUTERMANS et al Appln. No. 10/531,303

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /Mary J. Wilson'
Mary J. Wilson
Reg. No. 32,955

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100